

# Novavax to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights on November 4, 2021

October 18, 2021

GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2021 financial results and operational highlights on Thursday, November 4, 2021, following the close of U.S. financial markets. Details of the event and replay are as follows:

## Conference call details:

Date:	November 4, 2021
Time:	4:30 p.m. U.S. Eastern Daylight Time (EDT)
Dial-in number:	(877) 870-4263 (Domestic) or (412) 317-0790 (International)
Webcast:	<a href="http://www.novavax.com/events">www.novavax.com/events</a>

- *Participants will be prompted to request to join the Novavax, Inc. call.*
- *To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.*

## Replay details:

Date:	Available starting at 7:30 p.m. EDT, November 4, 2021 until 11:59 p.m. U.S. Standard Time, November 11, 2021
Dial-in number:	(877) 344-7529 (Domestic) or (412) 317-0088 (International)
Passcode:	10161242
Webcast:	<a href="http://www.novavax.com/events">www.novavax.com/events</a> , until February 4, 2022

## About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit [www.novavax.com](http://www.novavax.com) and connect with us on [Twitter](#) and [LinkedIn](#).

## Contacts:

### Investors

Novavax, Inc.

Erika Schultz | 240-268-2022

[ir@novavax.com](mailto:ir@novavax.com)

Solebury Trout

Alexandra Roy | 617-221-9197

[aroy@soleburytrout.com](mailto:aroy@soleburytrout.com)

### Media

Alison Chartan | 240-720-7804

Laura Keenan | 202-709-7521

[media@novavax.com](mailto:media@novavax.com)

SOURCE Novavax, Inc.

Image not found or type unknown